Redx Pharma plc Redx to present new scientific data at ESMO 2017
August 31 2017 - 3:00AM
RNS Non-Regulatory
TIDMREDX
Redx Pharma plc
31 August 2017
31 August 2017
REDX PHARMA PLC (in administration)
("Redx" or "the Company")
Redx to present new scientific data at ESMO 2017
Redx Pharma will present a poster on their planned
first-in-human clinical trial for RXC004 at the European Society
for Medical Oncology (ESMO) Annual Meeting, September 8-12, 2017,
in Madrid.
Session Date & Time September 9, 2017, 13:15 AM -14:15 GMT+1h
Session Title GASTROINTESTINAL TUMOURS, COLORECTAL
Presentation Title Identification of an RNF43 mutated gastric cancer patient population with potential
sensitivity
to porcupine inhibitor RXC004 and development of a complimentary ctDNA liquid biopsy assay
for patient screening
Session Location Hall 8
Abstract # 692P
First author Matilda Bingham
Abstract online https://cslide.ctimeetingtech.com/library/esmo/browse/search/2iw4#2Bb5o02mE
Iain Ross, Chairman, commented:
'We're delighted to present new scientific data on our most
advanced program, the Porcupine inhibitor RXC004 as it moves closer
to the clinic. We have a strong portfolio of research assets and
continue to look for novel opportunities in several therapeutic
classes in oncology and immunology.'
For further information, please contact:
Redx Pharma Plc (in administration)
Contact for the Joint Administrators: T: + 44 203
Chris French 005 4000
James Rossiter
Cantor Fitzgerald Europe (Nomad & T: +44 20
Broker) 7894 7000
Phil Davies
WG Partners LLP (Joint Broker) T: +44 20
3705 9330
Claes Spång/ Chris Lee/ David
Wilson
About Redx Pharma Plc (in administration)
Company website: redxpharma.com
Jason Baker and Miles Needham have been appointed as joint
administrators of Redx Pharma plc (in administration). The
company's affairs, business and property are being managed by the
joint administrators.
Redx is focused on the discovery and development of proprietary,
small molecule therapeutics to address areas of high, unmet medical
need, principally in cancer, infection and immunology, providing a
pipeline of assets to larger and emerging companies. By improving
the characteristics of existing drug classes to create highly
differentiated, novel, best-in-class drugs, Redx has already
established a broad portfolio of proprietary drug programs.
This information is provided by RNS
The company news service from the London Stock Exchange
END
NRASDWSWFFWSEIA
(END) Dow Jones Newswires
August 31, 2017 04:00 ET (08:00 GMT)
Redx Pharma (LSE:REDX)
Historical Stock Chart
From Apr 2024 to May 2024
Redx Pharma (LSE:REDX)
Historical Stock Chart
From May 2023 to May 2024